Entrepreneurial scientist set to advance
knowledge, efficacy and safety of medical cannabis
OTTAWA, Nov. 6, 2017 /CNW/ - National Access
Cannabis Corp. ("NAC" or the "Company") (TSX VENTURE: NAC),
Canada's best practices leader in
delivering secure, safe, and responsible access to legal medical
cannabis today announced that Dr. Tyler
Wish has joined the Company to establish and lead its
research and development division. In this executive role, Dr. Wish
will be responsible for furthering the Company's efforts to advance
knowledge of medicinal cannabis as a pharmaceutical product and to
enhance its efficacy and safety across multiple patient
populations.
"Dr. Wish's extensive entrepreneurial experience and scientific
background will be an important catalyst in driving NAC's
involvement in advancing the medicinal cannabis market through
greater scientific and technological opportunities," said
Mark Goliger, Chief Executive
Officer of National Access Cannabis. "As much excitement as there
is for the future of Canada's
recreational cannabis market, the global market for
cannabis-related science and technology offers even greater
opportunities. Tyler's initial focus will be on establishing
research programs to investigate the clinical utility of medicinal
cannabis for treating PTSD and Diabetes, both of which affect a
large number of Canadians, particularly Veterans and Indigenous
groups with whom NAC has established important partnerships."
"NAC has supported over 10,000 patients to date, helping them to
source, select and use legal medical cannabis in treatment of their
chronic and acute conditions," said Dr. Tyler Wish. "With this established and
trusted partnership between patients and physicians, NAC has a
unique opportunity and responsibility to take a leadership position
with respect to generating data, knowledge and insights that lead
to improving human health through the use of medicinal
cannabis."
Dr. Tyler Wish is a trained
clinical/molecular epidemiologist, as well as an accomplished
entrepreneur and life-science executive who was recently recognized
and appointed as 1 of 10 "Canadian Innovation Leaders" by the
Federal Minister of Innovation, Science and Economic Development.
Prior to joining NAC, Tyler was a founder and the Chief Executive
Officer of Sequence Bio, a privately-held biotechnology company
that lead a large-scale human genome sequencing initiative designed
to support genetic-driven drug discovery and precision
medicine.
The Company also announced today that it has retained LodeRock
Advisors Inc. ("LodeRock") for strategic investor relations and
capital markets communications services. Under the terms of the
Investor Relations agreement, NAC will pay LodeRock a monthly fee
of CAD $8,000 for ongoing strategic communication
services. Neither LodeRock nor its principals presently have any
other direct or indirect interest in NAC securities.
LodeRock Advisors is a group of senior capital markets
communications executives who develop and execute communications
programs in order to help companies achieve their capital markets
objectives and capture the full potential of their public listing.
The engagement of LodeRock remains subject to the approval of the
TSX Venture Exchange.
About National Access Cannabis
National Access Cannabis is Canada's best practices leader in delivering
secure, safe, and responsible access to legal medical cannabis. NAC
enables patients to gain knowledge and the legal medical
documentation required to navigate Canada's disparate network of authorized
Licensed Producers of Cannabis. Through its Canada-wide network of care centres, NAC has
partnered with health professionals to improve the quality of life
of its local members and provide services designed to inform,
educate and supply expert advice.
nationalaccesscannabis.com
National Access Cannabis Corp. is listed on the TSX Venture
Exchange under the symbol (TSXV: NAC).
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE National Access Cannabis Corp.